|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Susceptible infections,Severe campylobacter enteritis,Pertussis,Diphtheria,Chanroid,Legionnaire’s disease,Chlamydial infections,Legionnaire’s disease,Bronchitis,Pneumonia,Sinusitis,Trench fever,Acne,Prophylaxis of streptococcal infections in patients with evidence of rheumatic fever or heart disease,Treatment and prophylaxis of neonatal conjunctivitis.
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
May antagonise therapeutic effects lincomycin and clindamycin. Concurrent usage may lead to increased absorption of alcohol. Potentially Fatal: May potentiate actions of neuromuscular blockers, oral anticoagulants, ciclosporin, theophylline. Terfenadine, astemizole, cisapride toxicity increased. Food Interaction Increased absorption when taken with meals. Lab Interference False-positive urinary catecholamines. Falsely elevated serum-aspartate aminotransferase values.
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. pregnancy: Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Talal Sabouni
Yaser Habrawi , F.R.C.S.Ed
Dr. Faisal Dibsi
Dr. Tahsin Martini
Dr . Dirar Abboud
Samir Moussa M.D.
Dr. Samer Al-Jneidy
Dr. Hani Najjar